SCHEMBL4563335

SCHEMBL4563335

CNc1ncc2cc(-c3cc(NC(=O)Nc4cnn(C(C)(C)C)c4)c(F)cc3F)c(=O)n(C)c2n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.60
RAF1 P04049 3/20 0.60
SRC P12931 7/20 0.44
FGFR1 P11362 4/20 0.44
EGFR P00533 3/20 0.44
ABL1 P00519 7/20 0.41
SIK2 Q9H0K1 3/20 0.41
EPHA2 P29317 2/20 0.41
MAPK8 P45983 2/20 0.41
EPHB4 P54760 2/20 0.41
SIK1 P57059 2/20 0.41
SIK3 Q9Y2K2 2/20 0.41
GAK O14976 1/20 0.41
EPHA1 P21709 1/20 0.41
EPHA3 P29320 1/20 0.41
EPHB2 P29323 1/20 0.41
EPHB3 P54753 1/20 0.41
EPHB1 P54762 1/20 0.41
EPHA4 P54764 1/20 0.41
MAPK14 Q16539 6/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5066945 0.94 BRAF (0.69) BRAFRAF1SRCFGFR1EGFR
SCHEMBL5061721 0.94 BRAF (0.58) BRAFRAF1SRCFGFR1EGFR
SCHEMBL5061871 0.89 BRAF (0.53) BRAFRAF1SRCFGFR1EGFR
SCHEMBL5061920 0.88 BRAF (0.46) BRAFRAF1SRCFGFR1EGFR
SCHEMBL4563431 0.85 BRAF (0.58) BRAFRAF1SRCFGFR1EGFR
SCHEMBL5067058 0.84 BRAF (0.57) BRAFRAF1SRCFGFR1ABL1
SCHEMBL5066985 0.83 BRAF (0.56) BRAFRAF1SRCFGFR1ABL1
SCHEMBL5062769 0.83 RAF1 (0.58) BRAFRAF1SRCFGFR1ABL1
SCHEMBL5057699 0.83 RAF1 (0.51) BRAFRAF1SRCFGFR1EGFR
SCHEMBL4571002 0.83 BRAF (0.58) BRAFRAF1SRCFGFR1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US claimed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885SRC 417/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885SRC 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.